drugset / Trial / NCT00717067
Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess whether a dosing adjustment is needed in patients with renal impairment.
Timeline
- Start
- 2008-07
- Primary completion
- 2008-11
- Completion
- 2008-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Maraviroc | Other / unclassified | 150 mg | — |
| Subject | Maraviroc | Other / unclassified | 300 mg | — |
| Background | Ritonavir | Other / unclassified | 100 mg | — |
| Background | Saquinavir | Small molecule | 1000 mg | — |